On April 6, 2023 — Yaocheng Health Science&Technology (hereinafter referred to as "Yaocheng"), announced in Shanghai that it has officially become a strategic partner for clinical research informationization with RemeGen Co., Ltd. (hereinafter referred to as "RemeGen"). As a leading domestic biopharmaceutical company, RemeGen will widely adopt the AuroraPrime clinical research platform from China to support the R&D pipeline of clinical trials, while AlphaPrime will fully support RemeGen's exploration and implementation of clinical research informationization to accelerate innovation.

Ms. Su Na, Senior Vice President of RemeGen, said, "Clinical research is an important and rigorous scientific validation stage in the process of pharmaceutical innovation R&D. Every year, we invest a lot of manpower and time in the operation and maintenance of clinical trials. Obtaining high-quality trial data is the foundation for subsequent application analysis and value mining. If we can accelerate compliance, rigorous, and complex trial operation and data verification work, enterprises can make judgments and plans based on timely and reliable data support in an increasingly competitive environment. This not only optimizes cost investment but also maintains the core competitiveness of the enterprise. Selecting a technologically advanced, specialized intelligent system that focuses on life science innovation R&D and actively innovates with industry development to empower clinical R&D with leading technology is an important strategic intelligent transformation for RemeGen."

Ms. Wang Yujue, Director of Data Management at RemeGen, said, "RemeGen has a leading clinical research team in China, and we have been paying attention to the application of globally leading information technology in the clinical research stage. Last year, we conducted our first cooperation with AlphaPrime. The integration and friendly user experience of Prime Collect (EDC) and Prime Control (RTSM), as well as the professional and timely technical support of Yaocheng's team, left a deep impression on us. This year, we started comprehensive cooperation with Yaocheng. In addition to stable support in the trial data collection stage, Yaocheng's more innovative products have brought significant quality and efficiency improvements to data management. We look forward to the continuous intelligent innovation achievements of the Yaocheng team in a broader field."

Mr. Zhang Zhi, Chief Business Officer of Yaocheng, said, "We are honored to become RemeGen's strategic partner in the field of clinical research informationization. Based on our past successful cooperation experience, Yaocheng hopes to continue to empower RemeGen's innovative research with globally leading computer technology. Yaocheng's team has built a stable, integrated, open, and intelligent clinical research platform, AuroraPrime, which can flexibly support various informationization application scenarios in the clinical trial stage for enterprises. While ensuring data security, stability, and efficient circulation, we always take it as our responsibility to improve quality and efficiency. In multiple deep scenarios such as automated building of libraries, automated testing, medical coding, and data analysis, we have successfully used automation to improve the user experience of staff and reduce unnecessary costs. Yaocheng is always committed to building a data-driven intelligent solution for clinical research documents and data. This strategic cooperation with RemeGen will also focus on exploring more intelligent scenarios and jointly moving towards the future of clinical research informationization."

About RemeGen:

RemeGen was cofounded in 2008 by Mr. Weidong Wang founder of Rongchang Pharmaceuticals a leading traditional Chinese medicine company in China and Dr. Jianmin Fang a Canadian-American scientist. Headquartered in the coastal city of Yantai Shandong Province of China RemeGen has research labs and offices throughout China and the United States. RemeGen is committed to the discovery development and commercialization of innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune oncology and ophthalmic diseases.

About Yaocheng Health Science&Technology：

Yaocheng is focused on the clinical research and development field of life sciences, and is committed to creating a globally leading new generation of clinical research SaaS platform. It leverages cloud computing, big data, AI, and other technologies to empower the trial design, data management, and operation of life science research and development, ensuring clinical data consistency, improving design and execution efficiency, controlling cost input, accelerating the commercialization of innovative drugs and new medical devices, and benefiting human health.